ISSN:
1573-7217
Keywords:
adjuvant therapy
;
breast cancer
;
endocrine therapy
;
lymphocytes
;
tamoxifen
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary The blood lymphocyte population was studied in 23 breast cancer patients treated with adjuvant tamoxifen for 1.5–2 years, and in an equal number of control patients. The size and cellular composition of the blood lymphocyte population, as assessed by monoclonal antibodies directed against various subsets, did not differ between the two patient groups. However, lymphocytes from the tamoxifen-treated patients exhibited a significantly lower NK activity against K562 cells. In contrast, the proliferative response of lymphocytes to ConA was significantly higher. These results indicate that tamoxifen may modulate the immune system.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01805743
Permalink
